Medullary breast carcinoma
(Redirected from Medullary carcinoma of the breast)
Medullary Breast Carcinoma
Medullary breast carcinoma is a rare subtype of invasive breast cancer that accounts for approximately 3-5% of all breast cancer cases. It is characterized by the presence of distinct histological features and a relatively better prognosis compared to other types of breast cancer.
Symptoms[edit | edit source]
Patients with medullary breast carcinoma may present with a palpable breast lump, changes in breast size or shape, nipple discharge, or skin changes such as redness or dimpling. However, some cases may be asymptomatic and detected through routine screening mammograms.
Diagnosis[edit | edit source]
Diagnosis of medullary breast carcinoma is typically confirmed through a combination of imaging studies such as mammography, ultrasound, and magnetic resonance imaging (MRI), as well as a biopsy of the breast tissue. Histologically, medullary breast carcinoma is characterized by the presence of well-defined borders, high-grade tumor cells with prominent lymphocytic infiltrate, and syncytial growth pattern.
Treatment[edit | edit source]
The treatment approach for medullary breast carcinoma may involve a combination of surgery, chemotherapy, radiation therapy, and targeted therapy. Surgical options include lumpectomy or mastectomy, depending on the size and extent of the tumor. Chemotherapy regimens may be tailored based on the individual's tumor characteristics, and targeted therapies such as HER2 inhibitors may be considered for specific subtypes.
Prognosis[edit | edit source]
Overall, medullary breast carcinoma has a more favorable prognosis compared to other types of breast cancer. The 5-year survival rate for patients with medullary breast carcinoma is estimated to be around 85-90%. However, the prognosis may vary depending on factors such as tumor size, grade, lymph node involvement, and hormone receptor status.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD